Login to Your Account



Clinic Roundup


Wednesday, May 2, 2012
• Quark Pharmaceuticals Inc., of Fremont, Calif., said it amended its existing exclusive licensing agreement with Pfizer Inc., of New York, which enables Quark to perform a Phase IIa study assessing the effect of PF-655 on visual function in patients with moderate and advanced open-angle glaucoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription